Trial Profile
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-121 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2019
Price :
$35
*
At a glance
- Drugs TAS 121 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Taiho Pharmaceutical
- 12 Feb 2019 Results assessing safety, tolerability, pharmacokinetics, and efficacy of TAS-121, published in the Investigational New Drugs.
- 12 Oct 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress